Original Research

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

Robin L. Jones a,*, Mark J. Ratain b, Peter J. O'Dwyer c, Lillian L. Siu d, Jacek Jassem e, Jacques Medioni f,g, Maja DeJonge h, Charles Rudin i, Michael Sawyer j, David Khayat k, Ahmad Awada l, Judith M.P.G.M. de Vos-Geelen m, T.R. Jeffry Evans n, Jennifer Obel o, Bruce Brockstein o, Jacques DeGreve p, Jean-Francois Baurain q, Robert Maki r, David D’Adamo s, Mark Dickson t, Samir Undevia b, David Geary b, Linda Janisch b, Philippe L. Bedard d, Albiniru R. Abdul Razak d, Rebecca Kristeleit a, Joanna Vitfell-Rasmussen a, Ian Walters u, Stan B. Kaye a, Gary Schwartz v

a Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom
b University of Chicago, Chicago, IL, USA
c University of Pennsylvania, Philadelphia, PA, USA
d Princess Margaret Cancer Centre, Toronto, ON, USA
e Medical University of Gdansk, Gdansk, Poland
f Hôpital Européen Georges Pompidou, Paris, France
g Paris-Descartes University, Paris, France
h Erasmus University Medical Center, Rotterdam, the Netherlands
i Johns Hopkins University, Baltimore, MD, USA
j Cross Cancer Institute, Edmonton, AB, USA
k Petrie-Salpetriere Hospital, Paris, France
l Institut Jules Bordet, Brussels, Belgium
m Department of Internal Medicine, Division of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht UMC+, Maastricht, the Netherlands
n Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, United Kingdom
o North Shore University Health System, Evanston, IL, USA
p University Hospital Brussels, Brussels, Belgium
q Centre du Cancer, Cu Saint-Luc/UCL, Brussels, Belgium
r Monter Cancer Center, Lake Success, NY, USA
s Eisai Inc, Woodcliff Lake, NJ Previously Memorial Sloan-Kettering Cancer Center, New York, NY, USA
t Memorial Sloan-Kettering Cancer Center, New York, NY, USA
u Intensity Therapeutics Inc, Westport, CT Previously BMS, USA
v Columbia University, New York, NY, USA

* Corresponding author:
E-mail address: robin.jones4@nhs.net (R.L. Jones).

https://doi.org/10.1016/j.ejca.2019.07.024
0959-8049/© 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abstract  Background: Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas [STS], ovarian cancer, breast cancer, pancreatic cancer, non-small-cell lung cancer [NSCLC], gastric/esophageal cancer and transitional cell carcinoma [TCC]).

Patients and methods: During a 12-week open-label lead-in period, patients received brivanib 800 mg daily and were evaluated for FGF2 status by immunohistochemistry. Patients with stable disease at week 12 were randomised to brivanib or placebo. A study steering committee evaluated week 12 response to determine if enrolment in a tumour type would continue. The primary objective was progression-free survival (PFS) for brivanib versus placebo in patients with FGF2-positive tumours.

Results: A total of 595 patients were treated, and stable disease was observed at the week 12 randomisation point in all tumour types. Closure decisions were made for breast cancer, pancreatic cancer, NSCLC, gastric cancer and TCC. Criteria for expansion were met for STS and ovarian cancer. In 53 randomised patients with STS and FGF2-positive tumours, the median PFS was 2.8 months for brivanib and 1.4 months for placebo (hazard ratio [HR]: 0.58, p = 0.08). For all randomised patients with sarcomas, the median PFS was 2.8 months (95% confidence interval [CI]: 1.4–4.0) for those treated with brivanib compared with 1.4 months (95% CI: 1.3–1.6) for placebo (HR = 0.64, 95% CI: 0.38–1.07; p = 0.09). In the 36 randomised patients with ovarian cancer and FGF2-positive tumours, the median PFS was 4.0 (95% CI: 2.6–4.2) months for brivanib and 2.0 months (95% CI: 1.2–2.7) for placebo (HR: 0.56, 95% CI: 0.26–1.22). For all randomised patients with ovarian cancer, the median PFS in those randomised to brivanib was 4.0 months (95% CI: 2.6–4.2) and was 2.0 months (95% CI: 1.2–2.7) in those randomised to placebo (HR = 0.54, 95% CI: 0.25–1.17; p = 0.11).

Conclusion: Brivanib demonstrated activity in STS and ovarian cancer with an acceptable safety profile. FGF2 expression, as defined in the protocol, is not a predictive biomarker of the efficacy of brivanib.

© 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Brivanib is a small-molecule inhibitor of the vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) family of tyrosine kinase receptors [1,2]. The FGF pathway is involved in cell proliferation, differentiation, survival, angiogenesis and wound healing [3]. A variety of specific abnormalities of the FGF pathway (mutations, translocations, amplifications and overexpression) exist in multiple solid tumours [3]. A retrospective analysis of a phase I trial of brivanib suggested that patients with tumours expressing FGF2 by immunohistochemistry (IHC) were more likely to benefit from therapy [4].

The randomised discontinuation trial (RDT) is an approach to evaluate cytostatic drugs, incorporating a lead-in phase in which all patients are treated with the test drug, and was pivotal in the development of sorafenib for renal cell carcinoma [5,6]. Patients with disease progression after the lead-in phase withdraw from the trial and those with a partial response (PR) continue on test drugs. Patients with stable disease (SD) at the end of the lead-in phase are then randomised to receive the test drug or placebo [7]. This design has a number of advantages as all enrolled patients receive the test drug leading to rapid accrual [7].

We performed a randomised discontinuation phase II trial to evaluate the efficacy and safety of brivanib in multiple tumour types based on their known expression of FGF2 (soft-tissue sarcomas [STS], ovarian cancer, breast cancer, pancreatic cancer, non-small-cell lung cancer [NSCLC], gastric/esophageal cancer and transitional cell carcinoma [TCC]) and hypothesised that FGF2 overexpression would be predictive of efficacy [4].

2. Patients and methods

This trial was approved by the institutional review board or ethics committee at each participating centre.
The primary objective of this trial was to compare progression-free survival (PFS) for brivanib versus placebo in randomised patients (in one or more selected tumour types) with FGF2-positive tumours. PFS was also analysed in all randomised patients, regardless of FGF2 status. The secondary end-points included disease stabilisation rate, objective response rate and safety.

Central review of FGF2 status by IHC was performed based on criteria from a previous clinical trial [8]. Tumours were classified as FGF2 positive if the expression score was 1, 2 or 3 and negative if the expression score was 0. Analysis for correlation between grading intensity and efficacy was not performed.

Radiological response was evaluated every 6 weeks. For randomised patients, response was evaluated every 6 weeks up to week 36 and subsequently every 12 weeks. Radiological response was evaluated according to modified World Health Organization criteria using bidimensional measurements [5]. Complete response or PR was confirmed by a second tumour assessment 4 weeks or more after the response was first documented.

Safety assessments were performed on all patients for the entire treatment period. Adverse events (AEs) and laboratory values were graded according to National Cancer Institute Common Terminology Criteria (version 3.0).

2.1. Statistical methods

The primary analysis was the comparison of PFS between brivanib and placebo in the randomised FGF2-positive cohort. This comparison was performed separately for each tumour type (that was selected for expansion) using a 2-sided 10% level log-rank test with 80% power. No adjustment was made for multiple testing. Fifty-two events were required to detect a hazard ratio of 0.5, corresponding to a doubling in the median PFS for brivanib compared with placebo (i.e. 2–4 months). Assuming that 70 patients with FGF2-positive tumours were randomised during a 16-month period, 52 events were expected to be observed after 16 months.

The total number of randomised patients for the primary analysis in the STS and ovarian cohorts was lower than originally planned owing to the relatively low FGF2 positivity rate. As the required number of events in the FGF2-positive STS cohort was not reached, the sample size requirements (52 events required in the randomised period) were applied to the overall population rather than to the FGF2-positive population. Consequently, the statistical power of the primary analysis was lower than 80%. The alternative hypothesis around the effect size was made more stringent, and PFS comparison was conducted on all randomised patients (regardless of FGF2 status) to ensure 80% power.

Forty randomised patients with ovarian cancer (regardless of FGF2 status) were required to reach 28 events when comparing PFS for brivanib and placebo at a HR of 0.33, 2-sided alpha of 5% and power 80%.

The Kaplan–Meier product-limit method was used to estimate median PFS; its corresponding confidence interval (CI) was compared by the method used by Brockmeyer and Crowley [8]. For randomised patients, HR with the corresponding CI was calculated using the Cox proportional hazards model. Because all patients received brivanib at the same initial dose, the safety analysis was performed on the pooled population.

3. Results

Between June 2008 and August 2011, 595 patients with 7 tumour types were treated with brivanib within the phase II trial. The baseline characteristics of these patients are shown in Table 1. Most patients were female (377, 63%), and 290 patients (49%) had a PS of 0. This was a heavily pre-treated population, with 18% of patients having received 2 prior lines of systemic therapy and 55% having received ≥3 lines of therapy. The FGF2 status at the baseline and randomisation for all tumour types are displayed in Table 2. Owing to logistical issues, publication of this manuscript was delayed.
3.1. Efficacy

The randomisation rate (i.e. SD at week 12) for the overall population was 30%. In addition, objective responses were observed in a number of disease cohorts (Table 2), and these patients were continued on open-label brivanib. The SSC regularly reviewed Kaplan–Meier estimates of the conditional probability that a proportion of patients with a tumour type would reach the week 12 randomisation point before making a decision whether to continue to accrue patients with each tumour type. Closure decisions were made for the breast cancer, pancreatic cancer, NSCLC, gastric cancer and TCC tumour types based on evaluation by the SSC (≤42 patients per tumour type). Therefore, the primary end-point was not assessed in these tumours. The SSC determined that the criteria for expansion were met for STS and ovarian cancer.
3.2. Soft-tissue sarcomas

At the week 12 evaluation point, 7 patients with sarcomas (2.8%) had a PR, 4 of these had FGF2-positive tumours. Radiological responses were seen in angiosarcomas (n = 3, Fig. 1), synovial, endometrial stromal, follicular dendritic cell sarcomas and leiomyosarcoma (1 each). Time to response ranged from 1.1 to 2.8 months, and duration of response ranged from 3.2 to 8.4 months.

Seventy-six patients (34%) had SD and were randomised to receive brivanib (n = 37) or placebo (n = 36). Three randomised patients were not treated, two had Progressive disease (PD) at week 12 and were randomised in error, and one patient with SD was not treated. In 53 randomised patients with FGF2-positive tumours, the median PFS was 2.8 months for brivanib compared with 1.4 months for placebo (HR: 0.58, p = 0.08), Fig. 2B.

For all randomised patients with sarcomas, the median PFS was 2.8 months (95% CI: 1.4–4.0) for those treated with brivanib compared with 1.4 months (95% CI: 1.3–1.6) for placebo (HR = 0.64, 95% CI: 0.38–1.07; p = 0.09, Fig. 2A).

Seventy-five percent of patients randomised to placebo progressed by their first (after randomisation) scan. Among the 30 randomised patients whose disease progressed while on placebo and then crossed over to open-label brivanib, the median PFS was 4.1 months (95% CI: 2.8–6.2) (Fig. 2C). Most patients (87%; 95% CI: 69.3–96.2) had disease restabilisation on retreatment with brivanib. One additional brivanib-treated patient achieved a PR in the randomised period.

3.3. Ovarian cancer

A total of 126 patients with ovarian cancer were treated. At the week 12 randomisation point, 9 patients (8.2%) had a PR, and 43 (34%) had SD. Thirty-nine patients were randomised, 19 to brivanib and 20 to placebo.

In the 36 randomised patients with ovarian cancer and FGF2-positive tumours, the median PFS was 4.0 months (95% CI: 2.6–4.2) for those treated with brivanib and 2.0 months (95% CI: 1.2–2.7) for those given placebo (HR: 0.56, 95% CI: 0.26–1.22).

For all randomised patients with ovarian cancer, the median PFS in those randomised to brivanib was 4.0 months (95% CI: 2.6–4.2) and was 2.0 months (95% CI: 1.2–2.7) in those randomised to placebo (HR = 0.54, 95% CI: 0.25–1.17; p = 0.11).

Three patients achieved a PR to brivanib during the randomised period. The time to response for these patients was 6.7, 3.9 and 1.7 months.

Patients who crossed over from placebo to brivanib had a subsequent median PFS of 1.5 months (95% CI: 1.2–2.8).

3.4. Entire trial population

A post hoc Kaplan–Meier analysis was performed in all randomised patients (n = 152), irrespective of the tumour type. The median PFS for all randomised patients (stratified by tumour type and FGF2 status) was 2.8 months (95% CI: 2.2–3.9) for patients treated with brivanib and was 1.4 months (95% CI: 1.3–1.8) for those on placebo (HR: 0.6, 95% CI: 0.41–0.88). An unstratified analysis of all randomised patients showed similar results.

3.5. Safety

AEs (regardless of causality) that occurred in ≥10% of the overall trial population are shown in Table 3. The most common AEs (>25% of patients) were fatigue, nausea, vomiting, decreased appetite, hypertension and

Fig. 1. Clinical responses to brivanib in patients with angiosarcoma.
dizziness. The most common grade ≥III AEs (reported for >5% of patients, regardless of causality) were hypertension, fatigue, increased alanine aminotransferase, increased aspartate aminotransferase, dyspnoea, malignant neoplasm and abdominal pain.

AEs leading to discontinuation were reported for 143 (24%) patients. The most common AEs leading to discontinuation were disease progression (12/143, 8%), vomiting (11/143, 8%) and dyspnoea (11/143, 8%).

Serious AEs (SAEs) were reported for 45% of treated patients. The most common SAEs (≥2%, regardless of causality) were malignant neoplasm, vomiting, dehydration, dyspnoea, hypertension, abdominal pain and nausea.

Sixty-eight patients (11%) died within 30 days of the last dose of brivanib. The primary cause of death was disease progression (51/68, 75%). In 6 patients (2 breast cancer and 1 each of gastric cancer, ovarian cancer, pancreatic cancer and NSCLC), the cause of death was potentially drug toxicity, ascribed to multiorgan failure, cerebral haemorrhage, hypovolemic shock due to dissection of aortic aneurysm, intracranial haemorrhage, bowel perforation and pulmonary haemorrhage.

4. Discussion

This randomised discontinuation phase II trial suggests that brivanib may have activity in multiple solid
The results of our trial and the role of the VEGF and FGF pathways in the biology of sarcomas suggest that brivanib should be further evaluated. It is unclear whether the activity of brivanib is due to inhibition of the vascular endothelial growth factor receptor (VEGFR) or FGF receptor (FGFR). As the FGF pathway has a potential role as a mediator of resistance to VEGFR inhibitors, the simultaneous inhibition of the VEGFR/FGFR is rational [13].

In addition, objective responses were observed in ovarian, breast and gastric/esophageal cancer. Activated mutations of FGFR3 occur in 38–66% of non-invasive and in 15–20% of invasive urothelial cancer, with occasional observation of FGFR gene fusions [14,15]. The pan-FGFR inhibitor, erdafitinib, has been approved for FGFR-mutated urothelial carcinoma [16].

FGF2 expression, as defined in the protocol, did not appear to be a biomarker that could be used to select patients with responsive tumours. This was supported by several lines of evidence. First, the median PFS was similar in the FGF2-positive population and all treated patients, regardless of FGF2 status. Second, the proportion of FGF-positive patients at baseline was similar to that at randomisation. A better understanding of the FGF pathway may help to identify other markers of FGF dependence.

5. Conclusion

This randomised discontinuation phase II trial suggests that brivanib may have activity in STS and ovarian cancer. This trial showed that FGF2 expression is not a biomarker for brivanib.

Conflict of interest statement

Robin L Jones has been a consultant for Adaptimmune, Blueprint, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Lilly, Merck, Pharmamar, Tracon, Upto Date.

Mark Ratain reports receiving grants from AbbVie, Dicerna and Genentech, reports receiving personal fees from AbbVie, Amgen, Ascentage, Cyclacel, Elion Oncology, multiple generic pharmaceutical companies, Shionogi and Portola Pharmaceuticals, outside the submitted work, is a coinventor on patent US6395481B with royalties paid from Mayo Clinic, patent US20160239636A1 pending, patent US8877723B2 issued and patent EP1629111B1 with royalties paid from Mayo Clinic, and serves as a director and treasurer of the Value in Cancer Care Consortium.

Peter J. O’Dwyer reports research support from Pfizer, Genentech, BMS, GSK, Five Prime, Forty Seven, BBI, Novartis, Celgene, Incyte, Lilly / Imclone, Array, H3 Biomedicine and Taiho Pharma, has been consulting in the past 2 years for Genentech, Celgene and Array.

Table 3

Summary of adverse events (N = 595).

<table>
<thead>
<tr>
<th>Adverse event, n (%)</th>
<th>All grades</th>
<th>Grade III–V</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total patients with an event</td>
<td>591 (99)</td>
<td>423 (71)</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>301 (51)</td>
<td>276 (46)</td>
</tr>
<tr>
<td>Nausea</td>
<td>280 (47)</td>
<td>262 (44)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>198 (33)</td>
<td>177 (30)</td>
</tr>
<tr>
<td>Constipation</td>
<td>131 (22)</td>
<td>124 (21)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>118 (20)</td>
<td>85 (14)</td>
</tr>
<tr>
<td>Stomatitis</td>
<td>64 (11)</td>
<td>58 (10)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>382 (64)</td>
<td>303 (51)</td>
</tr>
<tr>
<td>Asthenia</td>
<td>65 (11)</td>
<td>49 (8)</td>
</tr>
<tr>
<td>Alanine aminotransferase increase</td>
<td>103 (17)</td>
<td>33 (6)</td>
</tr>
<tr>
<td>Aspartate aminotransferase increase</td>
<td>99 (17)</td>
<td>54 (9)</td>
</tr>
<tr>
<td>Weight decrease</td>
<td>91 (15)</td>
<td>87 (15)</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>269 (45)</td>
<td>246 (41)</td>
</tr>
<tr>
<td>Back pain</td>
<td>85 (14)</td>
<td>78 (13)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>181 (30)</td>
<td>176 (30)</td>
</tr>
<tr>
<td>Headache</td>
<td>148 (25)</td>
<td>140 (24)</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>101 (17)</td>
<td>68 (11)</td>
</tr>
<tr>
<td>Dysphonia</td>
<td>82 (14)</td>
<td>82 (14)</td>
</tr>
<tr>
<td>Cough</td>
<td>73 (12)</td>
<td>71 (12)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>234 (39)</td>
<td>156 (26)</td>
</tr>
</tbody>
</table>

AEs, adverse events. The list includes AEs (all grades, any relationship) that occurred in ≥10% of the treated patients pooled from 7 cohorts and AEs with onset on or after the first dosing date and on or before the last dosing date, +14 days.
provides expert testimony for Bayer and Lilly and is not a stock owner of any companies.

Lillian Siu serves as a consultant for Merck (compensated), Pfizer (compensated), Celgene (compensated), AstraZeneca/MedImmune (compensated), MorphoSys (compensated), Roche (compensated), Geneseq (compensated), Loxo (compensated), Onchorus (compensated), Symphogen (compensated), Seattle Genetics (compensated) and GSK (compensated), is not a member of the speaker’s bureau for any companies, reports grant/research support (clinical trials for institution) from Novartis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm Therapeutics, Inc., AstraZeneca/MedImmune, Merck, Celgene, Astellas, Bayer, AbbVie, Amgen, Symphogen, Intensity Therapeutics, Mirati and Shattucksm Avid, is a stockholder of Agios (spouse) and is not an employee of any companies.

Jacek Jassem serves as a speaker for AstraZeneca, Roche and Pfizer and reports advisory roles for AstraZeneca, BMS, Pfizer, MSD and Takeda and travel support from Roche.

Jacques Medioni reports honoraria and advisory roles from Pierre Fabre, AstraZeneca, Inveectys and Astellas.

Robert Maki reports consulting fees from Arcus, Bayer, Deciphera, Eisai, Immune Design, Janssen R&D, Karyopharm Therapeutics, Lilly, Novartis, Pfizer, Presage, Sarcoma Alliance for Research Through Collaboration (SARC), SpringWorks, American Board of Internal Medicine and UpToDate and reports institutional receipts for clinical trials from Bayer, Karyopharm, Lilly, Pfizer, Regeneron, Presage, Sarcoma Alliance for Research Through Collaboration (SARC), SpringWorks and Tracon.

Ian Walters is an employee/stock owner of BMS at the time of the study and is currently, a CEO/board member of several small companies, including one public company (Portage Biotech).

Joanna Vitfell-Rasmussen, Stan Kaye, Samir Undevia, Ahmad Awada and other authors report no conflict of interest/disclosure.

Funding

This trial was funded by the Bristol-Myers Squibb company.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ejca.2019.07.024.

References


[16] Loriot Y, Necchi A, Park SH, et al. Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): phase 2 continuous versus intermittent dosing. In: Genitourinary Cancers Symposium, 2018; February 8-10, 2018; San Francisco, California; 2018. Abstract 411.